Literature DB >> 24740840

Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297.

Mohammad A Alsenaidy1, Solomon Z Okbazghi1, Jae Hyun Kim1, Sangeeta B Joshi1, C Russell Middaugh1, Thomas J Tolbert1, David B Volkin1.   

Abstract

The structural integrity and conformational stability of various IgG1-Fc proteins produced from the yeast Pichia pastoris with different glycosylation site occupancy (di-, mono-, and nonglycosylated) were determined. In addition, the physical stability profiles of three different forms of nonglycosylated Fc molecules (varying amino-acid residues at site 297 in the CH 2 domain due to the point mutations and enzymatic digestion of the Fc glycoforms) were also examined. The physical stability of these IgG1-Fc glycoproteins was examined as a function of pH and temperature by high-throughput biophysical analysis using multiple techniques combined with data visualization tools (three index empirical phase diagrams and radar charts). Across the pH range of 4.0-6.0, the di- and monoglycosylated forms of the IgG1-Fc showed the highest and lowest levels of physical stability, respectively, with the nonglycosylated forms showing intermediate stability depending on solution pH. In the aglycosylated Fc proteins, the introduction of Asp (D) residues at site 297 (QQ vs. DN vs. DD forms) resulted in more subtle changes in structural integrity and physical stability depending on solution pH. The utility of evaluating the conformational stability profile differences between the various IgG1-Fc glycoproteins is discussed in the context of analytical comparability studies.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  Fc; IgG; conformation; formulation; glycosylation; mass spectrometry; monoclonal antibody; spectroscopy; stability

Mesh:

Substances:

Year:  2014        PMID: 24740840      PMCID: PMC4512762          DOI: 10.1002/jps.23975

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  45 in total

1.  Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain.

Authors:  T Shantha Raju; Bernard J Scallon
Journal:  Biochem Biophys Res Commun       Date:  2006-01-19       Impact factor: 3.575

2.  Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody.

Authors:  Josef Vlasak; Marie C Bussat; Shiyi Wang; Elsa Wagner-Rousset; Mark Schaefer; Christine Klinguer-Hamour; Marc Kirchmeier; Nathalie Corvaïa; Roxana Ionescu; Alain Beck
Journal:  Anal Biochem       Date:  2009-06-02       Impact factor: 3.365

3.  Comparison of LC and LC/MS methods for quantifying N-glycosylation in recombinant IgGs.

Authors:  Sandipan Sinha; Gary Pipes; Elizabeth M Topp; Pavel V Bondarenko; Michael J Treuheit; Himanshu S Gadgil
Journal:  J Am Soc Mass Spectrom       Date:  2008-07-16       Impact factor: 3.109

4.  Structure of asymmetric non-precipitating antibody: presence of a carbohydrate residue in only one Fab region of the molecule.

Authors:  M O Labeta; R A Margni; J Leoni; R A Binaghi
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

Review 5.  The impact of glycosylation on the biological function and structure of human immunoglobulins.

Authors:  James N Arnold; Mark R Wormald; Robert B Sim; Pauline M Rudd; Raymond A Dwek
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

6.  Using secretion to solve a solubility problem: high-yield expression in Escherichia coli and purification of the bacterial glycoamidase PNGase F.

Authors:  Trevor Loo; Mark L Patchett; Gillian E Norris; J Shaun Lott
Journal:  Protein Expr Purif       Date:  2002-02       Impact factor: 1.650

7.  Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.

Authors:  H R Koene; M Kleijer; J Algra; D Roos; A E von dem Borne; M de Haas
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

8.  pH dependent effect of glycosylation on protein stability.

Authors:  Wei Wang; Kris Antonsen; Y John Wang; D Q Wang
Journal:  Eur J Pharm Sci       Date:  2007-11-19       Impact factor: 4.384

9.  Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry.

Authors:  Damian Houde; Joseph Arndt; Wayne Domeier; Steven Berkowitz; John R Engen
Journal:  Anal Chem       Date:  2009-04-01       Impact factor: 6.986

Review 10.  Glycosylation as a strategy to improve antibody-based therapeutics.

Authors:  Roy Jefferis
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

View more
  16 in total

1.  Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.

Authors:  Ranajoy Majumdar; Reza Esfandiary; Steven M Bishop; Hardeep S Samra; C Russell Middaugh; David B Volkin; David D Weis
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  Advanced analyses of kinetic stabilities of iggs modified by mutations and glycosylation.

Authors:  Erik Sedlák; Jonas V Schaefer; Jozef Marek; Peter Gimeson; Andreas Plückthun
Journal:  Protein Sci       Date:  2015-06-11       Impact factor: 6.725

3.  Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.

Authors:  Karthik Pisupati; Alexander Benet; Yuwei Tian; Solomon Okbazghi; Jukyung Kang; Michael Ford; Sergei Saveliev; K Ilker Sen; Eric Carlson; Thomas J Tolbert; Brandon T Ruotolo; Steven P Schwendeman; Anna Schwendeman
Journal:  MAbs       Date:  2017-08-08       Impact factor: 5.857

4.  A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima.

Authors:  Karthik Pisupati; Yuwei Tian; Solomon Okbazghi; Alexander Benet; Rose Ackermann; Michael Ford; Sergei Saveliev; Christopher M Hosfield; Marjeta Urh; Eric Carlson; Christopher Becker; Thomas J Tolbert; Steven P Schwendeman; Brandon T Ruotolo; Anna Schwendeman
Journal:  Anal Chem       Date:  2017-04-17       Impact factor: 6.986

5.  Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis.

Authors:  Solomon Z Okbazghi; Apurva S More; Derek R White; Shaofeng Duan; Ishan S Shah; Sangeeta B Joshi; C Russell Middaugh; David B Volkin; Thomas J Tolbert
Journal:  J Pharm Sci       Date:  2016-01-09       Impact factor: 3.534

6.  Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc Glycoforms.

Authors:  Olivier Mozziconacci; Solomon Okbazghi; Apurva S More; David B Volkin; Thomas Tolbert; Christian Schöneich
Journal:  J Pharm Sci       Date:  2016-01-11       Impact factor: 3.534

7.  Synthesis of a Bifunctional Peptide Inhibitor-IgG1 Fc Fusion That Suppresses Experimental Autoimmune Encephalomyelitis.

Authors:  Derek R White; Zahra Khedri; Paul Kiptoo; Teruna J Siahaan; Thomas J Tolbert
Journal:  Bioconjug Chem       Date:  2017-06-22       Impact factor: 4.774

Review 8.  Effects of localized interactions and surface properties on stability of protein-based therapeutics.

Authors:  Brittney J Mills; Jennifer S Laurence Chadwick
Journal:  J Pharm Pharmacol       Date:  2016-11-10       Impact factor: 3.765

9.  Solution structure of deglycosylated human IgG1 shows the role of CH2 glycans in its conformation.

Authors:  Valentina A Spiteri; James Doutch; Robert P Rambo; Jayesh Gor; Paul A Dalby; Stephen J Perkins
Journal:  Biophys J       Date:  2021-03-04       Impact factor: 4.033

Review 10.  Process- and Product-Related Foulants in Virus Filtration.

Authors:  Solomon Isu; Xianghong Qian; Andrew L Zydney; S Ranil Wickramasinghe
Journal:  Bioengineering (Basel)       Date:  2022-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.